Danish pharmaceutical giant Novo Nordisk announced a major rebranding initiative, changing its consumer-facing name to Novo (诺和) and overhauling its corporate culture in a strategic bid to reclaim market share in the fiercely competitive weight-loss drug sector. The company stated that this transformation marks a new chapter in its corporate journey as it navigates intense rivalry and mounting investor pressure.

Facing aggressive competition from Eli Lilly and demands from shareholders eager for a new blockbuster drug, the company unveiled fresh operating principles centered on establishing clear priorities and simplifying business processes. These changes are designed to sharpen focus and boost operational efficiency across the organization.

On Monday, Novo Nordisk (NYSE: NVO) announced it would adopt "Novo" as its new external brand identity and refresh its corporate ethos, intensifying its efforts to capture a larger slice of the weight-loss market. The Danish company described the move as the opening of a significant new phase, coming at a time when it is defending its position against Eli Lilly's advances and responding to investor calls for clear clinical trial results and a sustainable long-term growth strategy. Details of the broader strategic adjustments are slated for the company's Capital Markets Day on September 21.

As part of the announcement, Novo introduced a comprehensive new brand system featuring the tagline "Lasting Health Starts Now." This messaging conveys a clear directive for patients to take immediate action toward their long-term health objectives rather than delaying. The company emphasized that its new brand communication aims to build closer ties and foster trust with the public and stakeholders by integrating "breakthrough science into everyday life."

Despite the positive reception of its oral Wegovy formulation, which saw prescriptions surpass 3 million by June, Novo's share price has declined approximately 15% year-to-date. The company also recently halted three clinical trials for an investigational cardiovascular drug. According to IQVIA data cited in Eli Lilly's earnings presentation, Novo commanded a 38.8% share of the weight-loss market in the second quarter, trailing significantly behind Eli Lilly's 60.9%.

The company clarified that Novo Nordisk remains its official legal name, a title derived from the merger of two former Danish competitors: Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium. This rebrand comes as the market shifts toward direct-to-consumer models and competition intensifies.

To secure a competitive edge, the pharmaceutical firm established four new corporate cultural tenets: innovating with patients at the core; enhancing business performance to "create greater value for all stakeholders"; establishing clear priorities and streamlining workflows; and maintaining an uncompromising stance on patient safety and ethical conduct.

Beyond the challenges, Novo has celebrated significant successes this year, particularly the launch of oral Wegovy. The oral weight-loss medication has experienced a robust market debut, securing a first-mover advantage over Eli Lilly's oral drug Foundayo by establishing a strong early presence in the segment.